Form: 10QSB

Optional form for quarterly and transition reports of small business issuers

May 13, 1996

Documents

Published on May 13, 1996



Exhibit 11

CYTOCLONAL PHARMACEUTICS INC.


COMPUTATION OF NET (LOSS) PER COMMON SHARE (2)
(unaudited)

Primary



Three Months Three Months
Ended Ended
March 31, March 31,
1995 1996
------------------ -------------------

Net (loss) ($ 765,000) ($ 657,000)

Add cumulative preferred dividend (79,000) (345,000)
----------- -----------

NET (LOSS) USED FOR COMPUTATION ($ 844,000) ($1,002,000)
=========== ===========

Weighted average number of common shares outstanding 5,220,000 7,569,918
----------- -----------

Shares issuable upon exercise of stock options and
warrants, net of shares assumed to be repurchased (1) 147,415 0
----------- -----------

Shares used for computation 5,367,415 7,569,918
=========== ===========

Net (loss) per common share ($ 0.16) ($ 0.13)
=========== ===========



Notes and Assumptions:
(1) The Company issued common stock and common stock equivalents for
consideration below the initial public offering price of $5.00.
Consequently, in accordance with Staff Accounting Bulletin 83 (during
the periods covered by statements of operation included in the
registration statement) the following methodology was used in
determining weighted average shares outstanding:
Stock issued in a one year period immediately prior to the
offering was treated as outstanding for the entire period and
repurchase of shares using the treasury stock method at an
offering price of $5.00.

(2) Adjusted to reflect retroactively, a 1 for 2.5 reverse stock split
effected on August 2, 1995.